Table 1.
Initial characteristics of patients
| n | % | |
| Age [median(range)] | 60 (28–77) | |
| Body mass index [median(range)] | 26 (16–66) | |
| Menopause | 39 | 65 |
| Smoking habit | 19 | 28.7 |
| Diabetes | 4 | 6 |
| High blood pressure | 15 | 22.7 |
| Lung pathologies | 3 | 4.5 |
| Heart pathologies | 3 | 4.5 |
| Side | ||
| Right | 31 | 47 |
| Left | 27 | 41 |
| Bilateral | 8 | 12 |
| Histologic subtype | ||
| IDC | 57 | 86,3 |
| ILC | 3 | 4,6 |
| Mixed IDC + ILC | 5 | 7,6 |
| Mucinous | 1 | 1,5 |
| Histologic grade | ||
| I | 1 | 1,5 |
| II | 28 | 42,4 |
| III | 37 | 56,1 |
| Molecular subtype | ||
| HR+/HER2- | 38 | 57.6 |
| HR-/HER2+ | 10 | 15.1 |
| HR+/HER2+ | 7 | 10.6 |
| Triple negative | 11 | 16.7 |
| Disease stage at tomotherapy treatment | ||
| Locally advanced | 9 | 13.6 |
| Metastatic | 57 | 86.4 |
| Antracyclin regimen prior HT | 38 | 57.7 |
| Concomitant systemic treatment with HT | ||
| Hormonotherapy | 27 | 40.9 |
| FUN regimen | 9 | 13.6 |
| Trastuzumab and Pertuzumab | 11 | 16.6 |
| Trastuzumab alone | 2 | 3 |
| Cyclophosphamide | 6 | 9 |
| Capecitabine | 6 | 9 |
| Docetaxel | 1 | 1.5 |
| Surgery before HT irradiation | ||
| Before HT irradiation | 26 | 39.4 |
| After HT irradiation | 14 | 21.2 |
FUN regimen, 5 fluorouracil and vinorelbine regimen; HR, hormone receptor; HT, helical tomotherapy; IDC, invasive ductal carcinoma; IDL, invasive lobular carcinoma.